

Phone: 732-39 PATIENT REFERF			8-2244	AsteraCancer(RHEUMATOLOG	-	
Patient Name:				Pt. DOB:	//	/
	Last	First	Middle			
Patient Address:						
Patient City:			Pt. State	e: Pt.	Zip:	
Patient Phone: ()	-		Pt. Heig	ht:	in.
DX:						
Insurance:				ID#:		
Referred by:				NPI#:		
Office Contact (Required):				Office Ph:()		
				Office Fax: ()		
Office Administra	tor (Requir	ed):	Admi	nistrator Ph:()		
Required Items/Inf Valid/signed pre (prescription on Copy of current i	ast Brunswick fusion Proce escription in aly valid for insurance ca	Edison UJerse ess: cluding name of m 6 months, includin ard	edication, exac g refills)	oe Robbinsville C	ons	Somerset
			e being treated	I must be mentioned	in report	
□ Allergies and cur				fellowing nego(s) of t	hia farma	
Has the patient init	-			following page(s) of t Yes 		
•		•		a prescription, and h		ng on
day of treatment. Please note:		· • •	•			
1. A Letter of Medi	ical Necessit	ty is required for all	patients receiv	ing their initial infusion	on at Astera (le	etter must
include diagnosis, p	previous tre	atments/response t	to treatments a	nd be on letterhead	with physician	signature).
2. Benefit investig	ations, cope	ay assistance and p	rior authorizat	ions will be handled	by the Astera _l	precert staff
if required by the p	ayer. <u>Right</u>	to auto-substitute	biosimilars ba	sed on payer's prefer	<u>ence</u> . Detailed	d clinical
	-		-	orization requests wh	-	
		-	-	eferring doctor's office	e during this p	rocess and
contact the patient	to discuss o	cost and financial as	ssistance option	ns.		

- 3. A pretreatment education session will be provided by an Advanced Practice Provider.
- 4. Once the infusion is complete, a follow-up notice will be faxed to the to the referring provider.

Please check the box for medication requested, attach required documentation as noted below, and fax all documents to our office at 844.683.2244. Once all documentation is received, we will contact your patient to schedule an appointment. Thank you!

Medication Required Current Lab Results

Note: Progress notes and labs must be completed within the previous 6 months for all new and renewed prescriptions.

Actemra CBC, Lipid Panel, Liver Function, PPD (prior to initiation) □ Benlysta(IV) None Cimzia CBC, Prior to initiation – PPD and Hep B Serology (Hep B surface antigen, Hep B surface antibody and Hep B core antibody) CMP, Dexa Scan within 2 years Evenity □ Confirm pt. has not had an MI or stroke within previous year □ Krystexxa G6PD Deficiency, Serum Uric Acid Levels, Confirm Oral Urate Lowering Agent Discontinued Prior to initiation – PPD and Hep B Serology (Hep B surface antigen, Hep B surface antibody and □ Orencia(IV) Hep B core antibody) □ Remicade/Inflectra (Biosimilar might be replaced if appropriate) CBC, Liver Function, Prior to initiation – PPD and Hep B Serology (Hep B surface antigen, Hep B surface antibody and Hep B core antibody) □ Rituxan/Riabni/Truxima/Ruxience (CMS approved indications only - Biosimilar might be replaced if appropriate) CBC, prior to initiation - Hep B Serology (Hep B surface antigen, Hep B surface antibody and Hep B core antibody) □ Confirm No Vaccinations within 4 Weeks of Therapy □ Saphnelo Up to date with all immunizations before treatment initiation and confirm no live or live attenuated vaccines are given concurrently. □ Simponi Aria(IV) CBC, Liver Function, Prior to initiation – PPD and Hep B Serology (Hep B surface antigen, Hep B surface antibody and Hep B core antibody) □ Stelara(IV) CBC, PPD Gene Testing (GBA – Velaglucerase Alfa) Vpriv

Page 2 7/23